[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-regeneration\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-regeneration":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,73,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100603876","effect-and-mechanism-of-alpps-operation-on-liver-regeneration-100603876",false,"NCT07142213","Effect and Mechanism of ALPPS Operation on Liver Regeneration","Effect and Mechanism of Combined Hepatectomy and Portal Vein Ligation Staged Hepatectomy (ALPPS) on Liver Regeneration in Patients With Hepatobiliary Malignancy","Inclusion Criteria:\n\n1. Age: Patients aged 18 to 75 years\n2. Diagnosis established: A diagnosis of hepatobiliary malignancy (including hepatocellular carcinoma and cholangiocarcinoma) was confirmed and evaluated as suitable for ALPPS surgery\n3. Liver function status: preoperative Child-Pugh score A or B, MELD score ≤15, with sufficient liver function reserve for operation\n4. Tumor characteristics: bilobal or complex tumors of the liver with large tumor areas requiring ALPPS to ensure adequate residual liver volume (FLR\u002FTLV\\\u003C30% or FLR\u002FBW\\\u003C0.5)\n5. Preoperative assessment: Imaging showed that future liver residual (FLR) was insufficient to support standard hepatectomy, and liver volume must be increased by ALPPS\n6. FLR enlargement: Postoperative assessment of FLR enlargement as expected (at least 30% enlargement or FLR\u002FBW above 0.5) for a second procedure\n7. No distant metastases: No unresectable extrahepatic metastases, except for resectable lung metastases\n\nExclusion Criteria:\n\n1. Preoperative FLR insufficiency: Residual liver volume (FLR) did not increase sufficiently after the first step (\\\u003C30% increase or FLR\u002FBW \\\u003C0.5) to be suitable for the second step\n2. Extrahepatic metastasis: unresectable distant metastasis, such as extensive metastasis of bone, lung, etc\n3. Severe liver disease: very poor liver function before surgery, Child-Pugh grade C or severe liver sclerosis during surgery (e.g. Metavir≥F3 or 30% or more hepatic steatosis)\n4. Major comorbidities: Major illnesses such as severe cardiovascular disease, kidney failure, or respiratory failure that do not tolerate major surgery\n5. Postoperative complications: Serious postoperative complications (such as liver failure, infection, etc.) after the first step are not suitable for the second step\n6. Evaluation of adverse surgery: After the first procedure, FLR blood supply or function is abnormal, affecting liver regeneration\n7. Pregnancy and lactation: pregnant or lactating women","ALL","18 Years","75 Years",{"count":20,"type":21},50,"ESTIMATED","1 Year","OBSERVATIONAL","Hepatobiliary malignancies-principally hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA)-are highly aggressive and often diagnosed at advanced stages. Curative-intent liver resection remains the standard for resectable disease; however, postoperative outcomes depend on an adequate functional future liver remnant (FLR). Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) induces rapid FLR hypertrophy and has expanded resection eligibility compared with conventional two-stage hepatectomy by shortening the interval to definitive resection.\n\nKey uncertainties persist regarding the quality of ALPPS-induced regeneration and its relationship to long-term oncologic outcomes, including recurrence and metastasis. This observational study enrolls patients deemed suitable for ALPPS at Peking Union Medical College Hospital. Perioperative care follows institutional standards; no therapeutic procedures are altered for research purposes. The investigators will collect clinically available liver tissue and relevant medical data obtained during standard surgical care to characterize cellular and molecular programs of regeneration across the ALPPS stages.\n\nHigh-throughput profiling-including single-cell and spatial transcriptomics-will be used to define cell-type composition, transcriptional states, and signaling pathways associated with regeneration. The primary objective is to describe cellular and gene-expression changes in regenerating liver induced by ALPPS. Secondary objectives include exploring associations between regenerative quality and short- and long-term clinical outcomes. Findings are expected to inform potential therapeutic targets and strategies to enhance safe regeneration and improve postoperative prognosis.",[26,27,28,29],"Hepato Cellular Carcinoma (HCC)","Hepatobiliary Cancers","Liver Cancer","Liver Regeneration",[31,32,33],"liver regeneration","ALPPS","hepatectomy","RECRUITING","2025-08-23",{"date":37,"type":38},"2025-08-26","ACTUAL",{"date":40,"type":38},"2020-01-01",{"date":42,"type":21},"2028-12-31",{"name":44,"class":45},"Haitao Zhao, MD","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":46},"100599539","to-study-effect-of-injection-pentoxifylline-on-liver-growth-after-major-liver-surgery-100599539","NCT07085806","To Study Effect of Injection Pentoxifylline on Liver Growth After Major Liver Surgery","Effect of Pentoxifylline on Liver Regeneration After Right Lobe Donor Hepatectomy: A Randomized Control Trial","Inclusion Criteria:\n\n* All live donors undergoing Right Donor Hepatectomy after ethical board clearance in the Department of HPB Surgery and Liver Transplantation\n\nExclusion Criteria:\n\n* Negative consent Hypersensitivity to Pentoxifylline","55 Years",{"count":56,"type":21},60,"INTERVENTIONAL",[59],"NA","Posthepatectomy liver failure (PHLF) remains a significant life-threatening problem after major hepatectomies. Pentoxifylline is shown to have potent vasodilating properties for peripheral blood vessels, along with the hepatic vasculature. In a Double-blinded, randomized, controlled trial (RCT) at a single tertiary care center (2006-2009) by Petrowsky, Henrik et al (Annals of Surgery, November 2010) on 101 Non-cirrhotic patients undergoing major Hepatectomy, they demonstrated beneficial effects of Pentoxifylline on regeneration of small remnant livers (RLBW ratio ≤ 1.2%). In mice model, pentoxifylline (Tian, Yinghua, et al Proceedings of the National Academy of Sciences 103.12 (2006)) is shown to confer protective effects against small-for-size syndrome in arterialized small-for-size liver transplantation. This Randomised control trial is being conducted to analyze the effect of Pentoxifylline supplementation in live donors undergoing donor hepatectomy with respect to markers of anatomical regeneration in a high volume liver transplant center in India.",[29],[63],"Role of Injection pentoxifylline in Liver regeneration after Right lobe Hepatectomy","2025-07-18",{"date":66,"type":38},"2025-07-25",{"date":68,"type":38},"2025-01-01",{"date":70,"type":21},"2025-07-31",{"name":72,"class":45},"Institute of Liver and Biliary Sciences, India",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":57,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":46},"100568483","novel-method-to-assess-hepatic-regeneration-and-predict-hepatic-related-morbidity-after-partial-hepatectomy-100568483","NCT06681818","Novel Method to Assess Hepatic Regeneration and Predict Hepatic Related Morbidity After Partial Hepatectomy","Postoperative Heme Oxygenase Induction and Carbon Monoxide Production as a Novel Method to Assess Hepatic Regeneration and Predict Hepatic Related Morbidity After Partial Hepatectomy","Inclusion Criteria:\n\n* Patient plans to have partial liver resection for primary liver pathology or metastatic disease\n* Patient is able to comprehend and willing to sign the written consent form\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years\n* Patients identified as members of a vulnerable population, except women of child bearing potential with negative pregnancy test",{"count":81,"type":21},125,[59],"the investigators will pursue two specific aims: (1) to monitor the extent of heme oxygenase induction (by measuring endogenous CO production) in relationship to the extent of hepatic resection (2) to assess the production of CO in patients following liver resection and correlate these findings to the rate of liver regeneration and liver function.",[85,29],"Liver Cancer Adult",[33],{"date":88,"type":38},"2025-07-23",{"date":90,"type":21},"2025-11-21",{"date":92,"type":21},"2039-01-01",{"name":94,"class":45},"Englewood Hospital and Medical Center",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":57,"phases":104,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":46},"100525798","application-of-high-dose-insulin-therapy-to-improve-liver-function-and-regeneration-100525798","NCT06126419","Application of High-dose Insulin Therapy to Improve Liver Function and Regeneration","Application of High-Dose Insulin Therapy Using a Hyperinsulinemic Normoglycemic Clamp to Improve Liver Function and Regeneration","Inclusion Criteria:\n\n* Age \\> 18 years old\n* Candidate for major liver resection\n* Resectable colorectal liver metastasis\n\nExclusion Criteria:\n\n* Inability to give consent\n* Type 1 diabetes mellitus\n* Uncontrolled blood glucose levels (fasting level \\> 10 mmol\u002FL)\n* Unresectable colorectal liver metastasis\n* Extrahepatic metastatic disease that is unresectable",{"count":103,"type":21},70,[59],"The primary objective of this interventional study is determine if the future liver remnant can be optimized by improving liver function pre-operatively in patients who are scheduled for major hepatectomy. The main questions it aims to answer are:\n\n1. Does high-dose insulin therapy improve liver function in the pre-operative setting?\n2. What is the effect of high-dose insulin therapy on liver function and liver regeneration after a liver venous deprivation (LVD) procedure?\n3. What is the relationship between volume hypertrophy and function in the regenerating liver? Participants will receive a 6-hour infusion of insulin and dextrose to maintain a hyperinsulinemic-normoglycemic state in the weeks prior to planned liver surgery to assess its effect on liver function measured by 99m-Tc-Mebrofenin hepatobiliary scintigraphy.",[107,108,29],"Liver Dysfunction","Liver Metastasis Colon Cancer",[110,111,112,113,114],"Hyperinsulinemic-Normoglycemic Clamp","High Dose Insulin Therapy","99mTc-Mebrofenin Hepatobiliary Scintigraphy","Colorectal Cancer Liver Metastasis","Liver Resection","2024-11-18",{"date":117,"type":38},"2024-11-20",{"date":119,"type":38},"2023-11-08",{"date":121,"type":21},"2026-12",{"name":123,"class":45},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre"]